Preclinical trials of new radiopharmaceuticals to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and reducing tumor volume. Designed specifically for ovarian cancer that is resistant to conventional treatments, new radiopharmaceuticals can be manufactured in 25 minutes at low cost, making them more efficient than other methods. This study was presented at the 2021 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.
According to the American Cancer Society, more than 20,000 women are diagnosed with ovarian cancer each year, and nearly 14,000 die of the disease. The 5-year survival rate for ovarian cancer patients is 49.1%. This is the fifth leading cause of cancer-related death in women.
In this study, researchers leveraged a new generator system to develop targeted alpha therapy Pb-214-TCMC-trastuzumab for the treatment of HER2-positive ovarian cancer.Mice with ovarian cancer cells and ovaries cancer Tumors were divided into three groups: a group treated with Pb-214-TCMC-trastuzumab, a group treated with Pb-214-TCMC-IgG, and an untreated control group. All groups were imaged over time to determine the effectiveness of the treatment.
Tumor signals in mice and cells treated with Pb-214-TCMC-trastuzumab were dramatically reduced during the course of the study, indicating therapeutic efficacy compared to Pb-214-TCMC-IgG and the control group. I did.There was not Harmful side effects From treatment determined by weight loss in all surviving animals.
“Pb-214’s short half-life of 27 minutes is ideal for fractionation. Alpha particles Niowave Inc in East Lansing, Michigan. Mike Zamiara, research author and president of the company, said: In the future, generator systems will be available in many therapeutic products for turnkey systems under development, providing reliable doses for improving patient care. “
Abstract 93. “Therapeutic Efficacy of Pb-214 Labeled Truth Tuzumab in Preclinical Models of Ovarian Cancer,” Abdullah Metebi, Comparative Medicine and Integrated Biology, Michigan State University, East Lansing, Michigan; Chelsea Nabuck, Michigan State University, East Lansing , Michigan State Institute for Quantitative Health Science and Engineering. Jinda Fan, Michigan State University, East Lansing, Michigan, Institute for Quantitative Health Science and Engineering, Department of Radiation Chemistry. Nathan Johnson, John Diemer, Terry Grimm, Mike Zamiara, Niowave, Inc. , Lansing, Michigan. Kurt Jin of the Institute of Radiology and Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, Michigan.
Provided by the Society of Nuclear Medicine and Molecular Imaging
Quote: Promising ovarian cancer treatments have proven to be effective and efficient (11 June 2021) 11 June 2021 https://medicalxpress.com/news/2021-06-ovarian- Obtained from cancer-treatment-effective-efficient.html
This document is subject to copyright. No part may be reproduced without written permission, except for private research or fair trade for research purposes. The content is provided for informational purposes only.
Promising ovarian cancer treatment proves effective and efficient Source link Promising ovarian cancer treatment proves effective and efficient